Abstract 614P
Background
Programmed Death Ligand-1 (PD-L1) is expressed in most type of cancer cells, including osteosarcoma. However, the role of PD-L1 expression in prognosis of osteosarcoma patients remains unclear. Thus, this study aims to investigate the association between PD-L1 expression and prognosis of Osteosarcoma patients.
Methods
Data was gathered from PubMed, PMC, and ScienceDirect databases on September 08, 2022, using keywords associated with PD-L1, Osteosarcoma in relation to the prognosis, which is measured by overall survival (OS), progression free survival (PFS), and event free survival (EFS). Publications included are associated with Osteosarcoma patients that are limited to English manuscripts within the last 10 years. Review articles, publications without full paper, and case report studies are excluded. The quality of each included study was assessed using the Newcastle Ottawa Scale (NOS), JBI Critical Appraisal for Quasi Experimental Studies, and Grading of recommendations, assessment, development, and evaluations (GRADE).
Results
A total of 7 studies consisting of 289 Osteosarcoma patients were included. All 6 studies have good quality based on NOS and one study categorized as include based on JBI. All 7 studies showed that high expression of PD-L1 correlates with poor prognosis of Osteosarcoma patients. Pooled analysis showed that high PD-L1 expression correlates with inferior OS (HR=2.03; 95%CI, 1.12-3.69; p=0.02) and PFS (HR= 1.18; 95%CI, 1.06-1.31; p=0.003). However, no significant association between PD-L1 expression and EFS (HR=1.05; 95%CI, 0.40-2.75; p=0.92). Based on GRADE, the result of this study is moderate in quality, as there is no inconsistency in results and publication biases are minimal.
Conclusions
Current studies demonstrated that high PD-L1 expression is associated with inferior OS and PFS, but not EFS in osteosarcoma patients, which warrants further prospective studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract